newsfilter
← Latest News
GlobeNewswire·

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss

Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg dose evaluated in prior studies may be due to a complex dose-response